certolizumab pegol · Cimzia

Antibody fragment

Also known as CDP870

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease, Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (7)
US
  • Polyarticular Juvenile Idiopathic Arthritis CIMZIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.Outside this platform's coverage
  • Ankylosing Spondylitis CIMZIA is indicated for the treatment of adults with active ankylosing spondylitis (AS). [see Clinical Studies (14.5) ]Outside this platform's coverage
  • Non-radiographic Axial Spondyloarthritis CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation [see Clinical Studies (14.6) ].
Product first approved 2008FDA label
CN
  • Moderate-to-severe rheumatoid arthritis (Import Drug License; reported 2019-07-22)
Product first approved 2019thepharmaletter.com
JP
  • Adult rheumatoid arthritis with inadequate response to conventional treatment (200 mg SC syringe)
Product first approved 2012newsroom.astellas.com
EU
  • Rheumatoid arthritis (initial EU authorisation; axSpA, PsA and psoriasis added later). EU never approved Crohn's disease.
Product first approved 2009EMA
CA
  • Rheumatoid arthritis in combination with methotrexate (Notice of Compliance)
Product first approved 2009dhpp.hpfb-dgpsa.ca

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (57)
Crohn's Disease
NCT01817972 · Gastroenterology Research of America
2013-03 – 2014-11 · Crohn's Disease
What this study did
NCT00358683 · UCB Pharma
started 2007-11 · Crohn's Disease
What this study did
NCT00354367 · UCB Pharma
started 2007-01 · Crohn Disease
What this study did
NCT00349752 · UCB Pharma
2006-11 – 2009-07 · Crohn's Disease
What this study did
NCT00307931 · UCB Pharma
2007-04 – 2008-08 · Crohn's Disease
What this study did
NCT00152490 · UCB Pharma
2003-12 – 2005-05 · Crohn's Disease
What this study did
Psoriasis
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT01864265 · University of Erlangen-Nürnberg Medical School
2013-07 – 2020-01-10 · Rheumatoid Arthritis
What this study did
NCT02319642 · UCB Pharma SA
2014-11 – 2016-12 · Rheumatoid Arthritis
What this study did
NCT01197066 · Korea Otsuka Pharmaceutical Co., Ltd.
2010-03 – 2016-11 · Rheumatoid Arthritis
What this study did
NCT02151851 · UCB Pharma SA, Belgium
2014-07 – 2016-06 · Rheumatoid Arthritis
What this study did
NCT01451203 · Astellas Pharma Inc
2011-10-11 – 2014-10-20 · Rheumatoid Arthritis
What this study did
NCT00851318 · Astellas Pharma Inc
2009-03 – 2013-06 · Rheumatoid Arthritis
What this study did
NCT01235598 · UCB Pharma
2010-12 – 2013-05 · Rheumatoid Arthritis
What this study did
NCT00850343 · Astellas Pharma Inc
2009-03 – 2013-05 · Rheumatoid Arthritis
What this study did
NCT00843778 · UCB Pharma
2009-01 – 2012-12 · Rheumatoid Arthritis
What this study did
NCT01374971 · Nathan Wei, MD, FACP, FACR:
2011-09 – 2012-07 · Rheumatoid Arthritis
What this study did
NCT01213017 · Oklahoma Medical Research Foundation
2010-09 – 2012-04 · Rheumatoid Arthritis
What this study did
NCT01292265 · UCB Pharma
2011-02 – 2012-01 · Rheumatoid Arthritis
What this study did
NCT00993317 · Korea Otsuka Pharmaceutical Co., Ltd.
2009-10 – 2011-08 · Rheumatoid Arthritis
What this study did
NCT00753454 · UCB Pharma
2008-09 – 2011-05 · Rheumatoid Arthritis
What this study did
NCT00717236 · UCB Pharma
2008-07 – 2011-03 · Rheumatoid Arthritis
What this study did
NCT00160693 · UCB Pharma
2003-03 – 2011-02 · Rheumatoid Arthritis
What this study did
NCT00674362 · UCB Pharma
2008-06 – 2010-12 · Rheumatoid Arthritis
What this study did
NCT00791921 · Otsuka Pharmaceutical Co., Ltd.
2008-11 – 2010-01 · Rheumatoid Arthritis
What this study did
NCT00548834 · UCB Pharma
2003-06 – 2004-07 · Rheumatoid Arthritis
What this study did
Phase 2/3 (2)
Psoriasis
NCT03051217 · UCB Biopharma S.P.R.L.
2017-02-21 – 2019-01-16 · Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis
What this study did
Rheumatoid Arthritis
NCT00791999 · Otsuka Pharmaceutical Co., Ltd.
2008-11 – 2011-01 · Rheumatoid Arthritis
What this study did
Phase 2 (13)
Crohn's Disease
NCT01190410 · UCB Pharma
2010-08 – 2017-11-27 · Crohn's Disease
What this study did
NCT00899678 · UCB Celltech
2009-04 – 2012-07 · Crohn's Disease
What this study did
NCT00329420 · UCB Pharma
2006-05 – 2008-05 · Crohn's Disease
What this study did
NCT00329550 · UCB Japan Co. Ltd.
2006-05 – 2008-04 · Crohn's Disease
What this study did
NCT00291668 · UCB Pharma
2006-03-02 – 2007-11-08 · Crohn's Disease
What this study did
Psoriasis
NCT00329303 · UCB Pharma
2006-04 – 2007-05 · Psoriasis
What this study did
NCT00245765 · UCB Pharma
2005-10 – 2006-11 · Chronic Plaque Psoriasis
What this study did
Rheumatoid Arthritis
NCT02293590 · Rüdiger B. Müller
2013-11 – 2018-01-15 · Rheumatoid Arthritis
What this study did
NCT02430909 · UCB Celltech
2015-04 – 2017-04 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03152058 · David Ware Branch
2017-05-17 – 2027-12 · High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
What this study did
NCT04991025 · Memorial Sloan Kettering Cancer Center
2022-10-19 – 2026-10 · Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
What this study did
NCT01090154 · University of Washington
2010-12-01 – 2021-12-10 · Ulcerative Colitis
What this study did
NCT03215277 · UCB Biopharma SRL
2017-10-04 – 2020-05-25 · Ankylosing Spondylitis
What this study did
Phase 1 (11)
Rheumatoid Arthritis
NCT03546335 · Robert Flavell, MD, PhD
2018-10-01 – 2029-03-31 · Rheumatoid Arthritis
What this study did
NCT04163016 · UCB Biopharma SRL
2020-06-19 – 2023-05-23 · Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
What this study did
NCT04740814 · UCB Biopharma SRL
2021-02-11 – 2022-06-27 · Rheumatoid Arthritis
What this study did
NCT02019602 · UCB BIOSCIENCES, Inc.
2014-01 – 2016-11 · Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
What this study did
NCT02154425 · UCB BIOSCIENCES, Inc.
2014-09 – 2016-01 · Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT02120807 · Memorial Sloan Kettering Cancer Center
2014-04-15 – 2023-01-24 · Stage IV Lung Adenocarcinoma
What this study did
NCT02365948 · UCB Pharma SA
2015-03 – 2015-08 · Healthy Subjects
What this study did
NCT01091220 · UCB Pharma
2010-03 – 2011-03 · Sperm Quality
What this study did
NCT00813774 · UCB Pharma
2008-02 – 2008-07 · Bioavailability Study on Healthy Volunteers
What this study did
NCT00845663 · UCB Pharma
2007-10 – 2008-04 · Healthy
What this study did
Phase 4 (18)
Crohn's Disease
NCT02597829 · Shafran Gastroenterology Center
2015-11 – 2018-10 · Crohn's Disease
What this study did
NCT01696942 · Milton S. Hershey Medical Center
2013-02 – 2016-06 · Crohn's Disease
What this study did
NCT01024647 · Atlanta Gastroenterology Associates
2009-12 – 2013-05 · Crohn's Disease
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
Rheumatoid Arthritis
NCT01491815 · Karolinska Institutet
2012-12-14 – 2023-12 · Rheumatoid Arthritis
What this study did
NCT02466581 · Karolinska Institutet
2015-02-03 – 2023-12 · Rheumatoid Arthritis
What this study did
NCT01602302 · Medical University of Graz
2012-06 – 2020-11-19 · Rheumatoid Arthritis
What this study did
NCT02353780 · Dr. Larry W. Moreland
2015-03 – 2018-11-30 · Rheumatoid Arthritis (RA)
What this study did
NCT02451748 · University of Illinois at Chicago
2015-08 – 2017-12 · Rheumatoid Arthritis
What this study did
NCT01295151 · Julia Brown
2011-08 – 2015-11 · Rheumatoid Arthritis
What this study did
NCT01443364 · UCB Italy s.p.a.
2011-12 – 2015-05 · Rheumatoid Arthritis
What this study did
NCT02132234 · Jagiellonian University
2013-06 – 2014-07 · Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Hypertension
What this study did
NCT01255761 · UCB Pharma
2010-11 – 2012-12 · Rheumatoid Arthritis
What this study did
NCT01147341 · Michael Schiff, MD
2010-07 – 2012-01 · Rheumatoid Arthritis
What this study did
NCT00580840 · UCB Pharma
2007-12 – 2011-03 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03020992 · UCB Biopharma SRL
2016-12-21 – 2020-01-23 · Axial Spondyloarthritis (axSpA), Anterior Uveitis (AU)
What this study did
Early phase / not applicable (3)
Crohn's Disease
NCT01053559 · Shafran Gastroenterology Center
2010-01 – 2013-09 · Crohn's Disease
What this study did
Rheumatoid Arthritis
NCT04569890 · RenJi Hospital
2020-12-01 – 2023-12-01 · Rheumatoid Arthritis, Pregnancy Related
What this study did
Other / comorbidity
NCT07491913 · Marmara University
2025-06-15 – 2027-12-15 · Takayasu Arteritis
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 4 (1)
Rheumatoid Arthritis
NCT03100253 · Mario Negri Institute for Pharmacological Research
2018-03-01 – 2021-12-31 · Rheumatoid Arthritis
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Rheumatoid Arthritis
NCT06028438 · Janssen Research & Development, LLC
2023-08-15 – 2024-10-29 · Arthritis, Rheumatoid
What this study did
Other / comorbidity
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
Phase 1 (1)
Other / comorbidity
NCT03293784 · Institut Claudius Regaud
2017-10-16 – 2023-08-10 · Melanoma
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Crohn's Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Certolizumab Pegol (Cimzia): this drugApprovedAntibody fragmentTNF-alphaWeak signal
NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed
NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg)
NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol).
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)ApprovedSmall moleculeGlucocorticoid receptorWeak signalFeatured results are safety only in this race
Budesonide (Ortikos)
ApprovedUS marketing discontinued
—Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine)
NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab)
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinPartial signal
NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1))
NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1))
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w)
NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg))
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinPartial signal
NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed
AfimkibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 3Cell therapyAllogeneic MSC therapyPartial signalNo reviewed efficacy summary in this indication
TH-SC01Phase 3Cell therapyMesenchymal stem cells (MSC)Weak signalNo reviewed efficacy summary in this indication
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 2/3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorPartial signal
NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed
AVB-114Phase 2Cell therapyImplantable cell/biomaterial constructPartial signal
NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29).
AZD7798Phase 2Monoclonal antibodyCCR9Weak signalFeatured results are safety only in this race
ExoFloPhase 2Cell therapyMSC-derived exosomesWeak signalFeatured results are safety only in this race
Golimumab (Simponi)Phase 2Monoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 2Small moleculemiR-124not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
EcoActivePhase 1/2Microbiome therapeuticBacteriophage (anti-AIEC)not yet gradedNo reviewed efficacy summary in this indication
Furestem-CDPhase 1/2Cell therapyAllogeneic MSC therapyWeak signalNo reviewed efficacy summary in this indication
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ALLO-ASCPhase 1Cell therapyAdipose-derived MSC therapyWeak signalNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Hemay007Phase 1Small moleculeTNF-alphaWeak signalNo reviewed efficacy summary in this indication
HRS-7085Phase 1Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
IPG11406Phase 1Small moleculeEBI2Weak signalFeatured results are safety only in this race
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 1Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
PALI-2108Phase 1Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
R-3750Phase 1Biologic (subtype unspecified)Dendritic cell targetingnot yet gradedNo reviewed efficacy summary in this indication
SOR102
Phase 1(overall)
Biologic (subtype unspecified)TNF-alpha, IL-23 p19
Weak signal(overall)
No reviewed efficacy summary in this indication
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ABBV-7066
—(overall)
UndisclosedIL-23 + TL1Anot yet gradedNo reviewed efficacy summary in this indication
BalinatunfibDiscontinuedSmall moleculeTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Firategrast (SB-683699)DiscontinuedSmall moleculeVLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4)not yet gradedNo reviewed efficacy summary in this indication
GSK2330811DiscontinuedMonoclonal antibodyOncostatin M (OSM)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cimzia (certolizumab pegol) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
December 2027 (2)
Phase 2High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant DisorderRecruiting
Est. primary completion 2027-12 · NCT03152058 · CT.gov ↗
What to watch
Early phase / not applicableTakayasu ArteritisRecruiting
Est. primary completion 2027-12-15 · NCT07491913 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
Phase 3Recurrent Unexplained Implantation FailureRecruiting
Est. primary completion 2029-04 · NCT05930613 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch

See the full readout calendar ↗